Medical data and technology company HeraMED (ASX:HMD) has received and accepted a further investment offer via a private placement of $1.02 million from three institutional investors.
The investors include a leading impact fund.
HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform.
HeraMED managing director and CEO Anoushka Gungadin said, “This strategic investment marks a transformative moment in our journey.
"This investment provides us with additional capital to drive our growth but also validates our commitment to delivering positive social impact in the healthcare sector.
"The global healthcare landscape faces mounting challenges in care accessibility, workforce shortages, and escalating costs. HeraCARE continues to demonstrate its potential as a comprehensive solution to these pressing issues, with an expanding body of evidence supporting its efficacy."
Ms Gungadin said the funds strengthen the company's financial position and provide an ability to drive the HeraCARE commercialisation strategy and build a sustainable pipeline of non-dilutive funding through grants and research partnerships.
"HeraMED will continue to expand its research collaborations and developing new evidence-based care models that can make a real difference in pregnancy outcomes across diverse communities. In 2024 the number and value of grants connected to remote maternity care significantly increased in Australia, the US and Europe," she said.